Clinical Trial Update: A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 [Phase 2]

View source ↗

Summary

Phase 2 double-blind, placebo-controlled safety and efficacy study of NA-831 in cognitive impairment disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• NA-831

Snippet

Sponsor: Biomed Industries, Inc. | Conditions: Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Status: COMPLETED